Search - tctmd.com

Displaying 601 - 620 of 3032

Sort: Relevancy | Date

News Features

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

Todd Neale

April 10, 2023

News Daily News

More AF Surveillance Needed in Chemotherapy Trials, Meta-analysis Hints

L.A. McKeown

April 06, 2023

News Daily News

Another Recall Warns of Unheralded Shutdowns With Cardiosave IABPs

Shelley Wood

March 31, 2023

News Daily News

Generic Dabigatran Lots Pulled for Nitrosamine Impurity

Michael O'Riordan

March 28, 2023

Presentation THT 2023

What Are the Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial

Presenter: Mandeep Mehra

March 20, 2023

Presentation THT 2023

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Presenter: William Abraham

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Changfu Wu

March 20, 2023

Presentation THT 2023

FDA Guidance on Meaningful Representation in Clinical Trials

Presenter: Bram Zuckerman

March 20, 2023

Presentation THT 2023

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

Presenter: Graham Nichol

March 20, 2023

Presentation THT 2023

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

Presenter: Navin Kapur

March 20, 2023

Presentation THT 2023

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Presenter: Gregg Stone

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Mauro Moscucci

March 20, 2023

Presentation THT 2023

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

Presenter: Maria Rosa Costanzo

March 20, 2023

Presentation THT 2023

Invasive Investigational Device IDE Studies: For Diuretic-Resistant Patients Only?

Presenter: Ulrich Jorde

March 20, 2023

Presentation THT 2023

FDA Introduction

Presenter: Meir Shinnar

March 20, 2023

News Daily News

Second Recall in Less Than 2 Months for Cardiosave IABPs

L.A. McKeown

March 17, 2023

News Daily News

SAFE-AAA Flags Ongoing EVAR Device Risk and Urges More Surveillance

L.A. McKeown

March 16, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

FDA Alert: Possible Early Deterioration of Abbott Trifecta SAVR Valves

Todd Neale

February 27, 2023

Advertisement

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

More AF Surveillance Needed in Chemotherapy Trials, Meta-analysis Hints

Another Recall Warns of Unheralded Shutdowns With Cardiosave IABPs

Generic Dabigatran Lots Pulled for Nitrosamine Impurity

What Are the Pros and Cons of the Win Ratio as the Primary Endpoint for Pivotal Heart Failure Trial

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

FDA Introduction

FDA Guidance on Meaningful Representation in Clinical Trials

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial Considering Best-Practices & Escalation of Therapy? What Are The Key Treatment Protocol Elements?

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

FDA Introduction

What Are Clinically Meaningful and Practical Pivotal Trial Endpoints for Effectiveness and Safety to Demonstrate an Acceptable Benefit-Risk Profile?

Invasive Investigational Device IDE Studies: For Diuretic-Resistant Patients Only?

FDA Introduction

Second Recall in Less Than 2 Months for Cardiosave IABPs

SAFE-AAA Flags Ongoing EVAR Device Risk and Urges More Surveillance

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

FDA Alert: Possible Early Deterioration of Abbott Trifecta SAVR Valves

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content